These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38021043)

  • 1. A Systematic Immune and Prognostic Analysis of CD48 Interaction with Tumor Microenvironment in Pan-Cancer.
    He M; Yu J; Chen S; Mi H
    Int J Gen Med; 2023; 16():5255-5269. PubMed ID: 38021043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
    Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
    Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Cancer Analysis Revealed
    Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
    J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifies microtubule-binding protein
    Wang W; Zhang J; Wang Y; Xu Y; Zhang S
    Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of
    Zhang S; Xiong H; Yang J; Yuan X
    Front Mol Biosci; 2021; 8():792154. PubMed ID: 35155565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary exploration of the potential biological functions and prognosis values of RAB4B in pan-cancer combing with experimental validation in BLCA.
    Li K; Liang S; Mi H
    Transl Cancer Res; 2024 Feb; 13(2):613-633. PubMed ID: 38482438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of
    Liu J; Zhu B; Chen J; Cao Y
    Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic analysis of
    Jiang Y; Wang X; Li L; He J; Jin Q; Long D; Liu C; Zhou W; Liu K
    Front Genet; 2022; 13():926943. PubMed ID: 35991552
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
    Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma.
    Liu C; Qu Z; Zhao H; Wang P; Zhan C; Zhang Y
    BMC Bioinformatics; 2023 May; 24(1):192. PubMed ID: 37170221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
    Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5.
    Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW
    Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
    Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
    Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
    Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KCNN4 is a Potential Biomarker for Predicting Cancer Prognosis and an Essential Molecule that Remodels Various Components in the Tumor Microenvironment: A Pan-Cancer Study.
    Chen S; Su X; Mo Z
    Front Mol Biosci; 2022; 9():812815. PubMed ID: 35720112
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 19. Association analysis of FXYD5 with prognosis and immunological characteristics across pan-cancer.
    Bai Y; Li L; Li J; Lu X
    Heliyon; 2024 May; 10(9):e30727. PubMed ID: 38774095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
    Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
    Front Immunol; 2021; 12():812713. PubMed ID: 35069601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.